We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
+6.61%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$4.51B
AUM Growth
+$203K
Cap. Flow
+$16.7M
Cap. Flow %
0.37%
Top 10 Hldgs %
82.68%
Holding
115
New
24
Increased
20
Reduced
23
Closed
20

Top Buys

Rank Stock Value
1
XLRN
Acceleron Pharma
XLRN
+$15.8M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$11.2M
3
MET icon
MetLife
MET
+$10.7M
4
TSRO
TESARO, Inc.
TSRO
+$8.14M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$7.5M

Top Sells

Rank Stock Value
1
INCY icon
Incyte
INCY
+$41.4M
2
BLUE
bluebird bio
BLUE
+$13.6M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$12.9M
4
CELG
Celgene Corp
CELG
+$12M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$9.24M

Sector Composition

Rank Sector Weight
1 Consumer Staples 44.81%
2 Healthcare 29.44%
3 Miscellaneous 13.88%
4 Consumer Discretionary 10.77%
5 Financials 0.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FOLD
101
CALL
DELISTED
Amicus Therapeutics
FOLD
– –
-650,000
Closed -$3.23M
FXI icon
102
CALL
iShares China Large-Cap ETF
FXI
$4.1B
– –
-1,000,000
Closed -$34.7M
INCY icon
103
CALL
Incyte
INCY
$24.7B
– –
-100,000
Closed -$10M
IONS icon
104
CALL
Ionis Pharmaceuticals
IONS
$7.85B
– –
-200,000
Closed -$9.57M
JD icon
105
CALL
JD.com
JD
$36.6B
– –
-250,000
Closed -$6.36M
LLY icon
106
CALL
Eli Lilly
LLY
$1.01T
– –
-200,000
Closed -$14.7M
MS icon
107
CALL
Morgan Stanley
MS
$324B
– –
-150,000
Closed -$6.34M
NBIX icon
108
CALL
Neurocrine Biosciences
NBIX
$15.2B
– –
-100,000
Closed -$3.87M
PFE icon
109
CALL
Pfizer
PFE
$157B
– –
-527,000
Closed -$16.2M
WMT icon
110
CALL
Walmart Inc
WMT
$858B
– –
-1,500,000
Closed -$34.6M
CLVS
111
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-50,000
Closed -$2.22M
ALXN
112
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-350,000
Closed -$42.8M
CEMP
113
DELISTED
Cempra, Inc.
CEMP
– –
-200,000
Closed -$560K
CLCD
114
DELISTED
CoLucid Pharmaceuticals, Inc.
CLCD
– –
-5,575
Closed -$203K
CELG
115
DELISTED
Celgene Corp
CELG
– –
-100,000
Closed -$12M
1 2 3 4
5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q1 2017 Portfolio in Review

As of Q1 2017, Artal Group held 115 positions worth $4.51B, up 0% from $4.5B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Artal Group's Q1 2017 filing shows 24 new, 20 increased, 23 reduced and 20 closed positions. Its largest new stake was Ionis Pharmaceuticals: 250,000 shares worth $10.1M. The largest sale was Incyte, an estimated $41.4M.

By sector, the portfolio is most concentrated in Consumer Staples at 45% of assets, down from 47% a quarter earlier, followed by Healthcare and Miscellaneous.

  • Artal Group's largest Q1 2017 buy was Ionis Pharmaceuticals: 250,000 shares worth $10.1M.
  • Artal Group added most to Acceleron Pharma in Q1 2017, an estimated $15.8M increase.
  • Artal Group's biggest Q1 2017 reduction was Incyte, cutting an estimated $41.4M.
  • Artal Group fully exited Celgene Corp in Q1 2017, selling an estimated $12M.
  • Artal Group's ten largest holdings make up 83% of its $4.51B portfolio in Q1 2017.
  • Artal Group opened 24 new positions and closed 20 in Q1 2017.
  • Artal Group's portfolio value rose 0% quarter-over-quarter to $4.51B.

Based on Artal Group's 13F filing for Q1 2017, filed 15 May 2017.